如今，"广货北上"浪潮持续深化。从日常消费的烟火气到产业升级的创新力，岭南智造已深度融入内蒙 古的发展肌理，粤蒙合作也从最初的商品流通迈向产业协同、理念相融的新阶段。 日前，内蒙古广东商会会长王鹏翔在接受羊城晚报记者专访时，围绕粤蒙经贸合作、广货北上等话题， 从行业视角出发，分享了诸多见解与思考。 羊城晚报：您如何看待广货在内蒙古的变迁？ 王鹏翔：二十世纪八九十年代，广东的纺织品、日用百货、家具家电率先进入内蒙古市场，解决了"有 没有"的问题，那时广货代表的是"新潮"和"洋气"。现在随着消费升级，广货在内蒙古已经进化为"高品 质"与"智能化"的代名词。从智能手机到新能源汽车，再到高端医疗器械，广东的硬核科技产品正在重 塑内蒙古的消费和生产方式。 羊城晚报：目前有多少广东企业在内蒙古投资？主要分布在哪些行业？ 王鹏翔：据不完全统计，目前，在内蒙古投资兴业的广东籍企业及关联项目超过2000家，实际投资额已 超数千亿元规模，是内蒙古外来投资的重要力量。内蒙古广东商会的会员企业分布广泛，呈现出"传统 产业稳底盘，新兴产业挑大梁"的格局。早期广东商人主要集中在商贸物流、房地产、餐饮服务等领 域。随着两地合作深入，越来越 ...

Core Viewpoint - The Heilongjiang Provincial Government has issued a set of policy measures to support the high-quality development of the biomanufacturing industry, aiming to enhance technological innovation, promote industrial expansion, and ensure resource allocation to create competitive advantages and seize future development opportunities [2][7]. Group 1: Enhancing Technological Innovation - Support for the construction of innovation platforms in biomanufacturing through collaboration between enterprises and research institutions, with financial rewards for approved national and provincial platforms [3][8]. - Encouragement for tackling core technological challenges in biomanufacturing, with provincial financial support for approved key research projects [3][8]. - Incentives for enterprises to increase R&D investment, with subsidies for qualifying expenditures exceeding 500,000 yuan, matched by provincial and municipal funding [3][8]. - Support for the establishment of pilot testing and verification platforms, with potential subsidies of up to 1 million yuan based on performance evaluations [3][8]. - Promotion of technology transfer activities, providing funding for contracts exceeding 1 million yuan for technology purchases from research institutions [3][8]. Group 2: Promoting Industrial Expansion and Quality Improvement - Financial support for new biomanufacturing projects in key sectors, with subsidies of up to 5 million yuan for fixed asset investments of 20 million yuan or more [4][9]. - Assistance for equipment upgrades in biomanufacturing enterprises to enhance production efficiency and reduce costs [4][9]. - Support for digital transformation using AI, big data, and IoT technologies, with subsidies for recognized digital workshops and smart factories [4][9]. Group 3: Supporting Key Sector Development - Focus on strengthening the biopharmaceutical sector with financial support for clinical trials and production of new drugs and high-end medical devices, with potential rewards of up to 1.5 million yuan [4][9]. - Encouragement for the development of new food products, with one-time rewards for approved new food materials and additives [4][9]. - Promotion of biochemicals with high added value, providing rewards for significant sales achievements in new products [4][9]. Group 4: Resource Allocation and Financial Support - Support for the construction of biomanufacturing parks and infrastructure, with potential bond funding for qualifying projects [5][10]. - Inclusion of biomanufacturing enterprises in key resource allocation for utilities, ensuring priority in energy supply [5][10]. - Financial services support for biomanufacturing enterprises to facilitate listing and access to capital markets, including innovative loan products [5][10]. Group 5: Intellectual Property and Talent Development - Strengthening intellectual property protection for biomanufacturing innovations, with services to expedite patent applications [10][11]. - Encouragement for educational institutions to develop relevant programs and attract high-level talent to the biomanufacturing sector [10][11]. Implementation Timeline - The policy measures are effective from the date of issuance until December 31, 2028, with provisions for adjustments based on national and provincial policy changes [10].

Group 1 - The company focuses on the research and commercialization of biomedical materials and high-end medical devices [2] - The company aims to leverage the development opportunities presented by "expanding domestic demand and promoting consumption" [2] - The company plans to continuously expand its layout in the healthcare sector [2]

Core Insights - The development logic of medical technology is shifting due to the upgrade of medical demand, engineering technology iteration, and the evolution of payment systems, with a focus on system-level solutions and industry collaboration [2] - The third Global MedTech Conference will be held on June 12, 2026, at the Zhongguancun Conference Center, aiming to connect engineering, clinical, corporate, capital, and regulatory aspects of medical technology innovation [2] - The conference will feature the release of a white paper, award evaluations, and multi-theme forums to present global medical technology innovation trends [2] Conference Overview - The conference will include a brand exhibition area for showcasing innovative technologies, products, and solutions, with reservations now open [3] - The second Global MedTech Conference highlighted the release of the "2026 Global Medical Technology Innovation White Paper" and awarded 11 innovation awards [4][6][7] - The white paper will provide a comprehensive framework for industry observation, focusing on technological evolution, product changes, corporate development models, and industry patterns [13][14] Key Themes - The white paper will cover high-end medical devices, surgical robots, medical imaging, digital healthcare, and the trends in registration and commercialization [15] - The conference will also feature awards for various categories, emphasizing long-term capabilities and systemic innovation [16][20] - Multi-theme forums will address topics such as medical technology innovation trends, engineering technology changes, and the commercialization path from R&D to market [17] Audience and Participation - The conference targets a diverse audience, including clinical experts, medical technology company leaders, industry observers, and investment representatives [21] - Sponsorship opportunities will provide structured, compliant, and sustainable collaboration paths for companies [22] - The event is positioned as an industry-focused, research-oriented conference rather than a purely academic or promotional meeting [23]

（来源：劳动午报） 现场，院校、东城区与北京国有资本运营管理有限公司签约发布目标规模40亿元的"协和创新港"成果转 化基金，通用健康、华润医药、国药集团、中发展集团、联影集团、海尔集团、数坤科技、中欧医药健 康产业同学会、东城国资公司等9家"协和创新港"合作伙伴意向签约，并向"协和创新港"首席科学家颁 发聘书，向药物所、阜外医院等20余家首批入港项目及平台单位授牌。 据了解，"协和创新港"聚焦创新药物、新型疫苗、高端医疗器械、人工智能医疗等重点领域，构建"源 头创新-临床验证-成果转化-产业落地"的全链条闭环生态体系，形成"研发在院校、转化在东城、辐射京 津冀、带动全中国"的特色发展格局。该项目将分三阶段推进，起步区已完成改造并投入使用，计划到 2030年累计转化一批重大创新项目，培育数十家"协和系"高新技术企业，形成生物医药产业集群。东城 区将为项目提供空间载体、政策资源等全方位支持，双方将通过共建转化平台、共育专业人才，合力打 造医药健康创新策源地。 本报讯（记者 边磊） 近日，由中国医学科学院北京协和医学院（以下简称"院校"）与东城区委、东城 区人民政府主办的"协和创新港"项目启动会举行。会上，院校与东 ...

Core Viewpoint - The Shanghai government report for 2026 indicates a GDP growth target of around 5% for the city, maintaining the same target set for 2025, reflecting a shift towards high-quality development and a focus on building a self-reliant industrial and supply chain system [2][6]. Economic Performance - In 2025, Shanghai's GDP reached 5.67 trillion yuan, growing by 5.4%, which was better than expected [1]. - The total retail sales of consumer goods in Shanghai grew by 4.6% in 2025, surpassing the national average growth rate of 3.7% and reversing a decline of 3.1% in 2024 [1][6]. Consumption and Retail Strategies - Shanghai implemented various initiatives to boost consumption in 2025, including the issuance of "Le Shanghai" service consumption vouchers and the promotion of night economy and cultural tourism events [5][7]. - The number of tax refund stores for outbound tourists increased to 1,837, a growth of 136%, contributing significantly to the retail sales growth [6]. Industrial Development - The three leading industries in Shanghai—integrated circuits, biomedicine, and artificial intelligence—surpassed a combined scale of 2 trillion yuan in 2025 [8]. - Shanghai's focus on high-end industrial structure is evident, with significant advancements in strategic emerging industries [2][8]. Innovation and R&D - In 2025, Shanghai's total R&D expenditure was approximately 4.5% of its GDP, with a target of increasing this to 4.6% in 2026 [9]. - The city aims to enhance its innovation capabilities by establishing high-quality incubators and concept verification platforms, and by promoting the integration of technology and industry [8][9].

Core Viewpoint - The Shanghai government aims for a GDP growth of around 5% for the year, with a focus on developing future industries and enhancing the modern industrial system [1][2][3] Economic Goals - The expected GDP growth for Shanghai in 2026 is also around 5%, with a target GDP of 5.67 trillion yuan by 2025, reflecting a growth of 5.4% [2] - Local general public budget revenue is projected to reach 850 billion yuan, with a growth of 1.5% [2] - The report sets a goal for R&D expenditure to be approximately 4.6% of the city's GDP, with an urban unemployment rate targeted to remain within 5% [2] Industry Development - The report emphasizes the cultivation of future industries such as brain-computer interfaces and fourth-generation semiconductors [3] - Implementation of the "Artificial Intelligence +" initiative is highlighted, focusing on enhancing computing power infrastructure and promoting the use of new intelligent terminals and models [3] - The construction of high-level innovation communities and the development of specialized industrial parks are prioritized [3] Investment and Infrastructure - A total of 255 billion yuan is planned for major engineering investments this year, including the construction of various metro lines and significant infrastructure projects [4] - The report outlines the initiation of several key transportation projects, including the extension of existing metro lines and the construction of new railways [4] Financial Reforms - The report calls for deepening financial system reforms and enhancing the construction of the Sci-Tech Innovation Board [5] - It aims to improve the connectivity of bond markets and explore the establishment of an offshore financial system [5] - There is a focus on fostering long-term and patient capital, enhancing the integration of finance and industry, and supporting sectors such as technology innovation and green development [5] Social Services - The report includes plans to reform elderly care services, with the addition of 2,000 cognitive care beds and 200 community-based elderly service stations [5] - It emphasizes the need for diverse services in community elderly care, including meal assistance and medical support [5]

Group 1 - The "Xiehe Innovation Port" project was officially launched on February 2, with a cooperation agreement signed between the Chinese Academy of Medical Sciences Peking Union Medical College and the Dongcheng District government [2][3] - The project aims to focus on key areas such as innovative drugs, new vaccines, high-end medical devices, and artificial intelligence in healthcare, creating a benchmark innovation platform that integrates achievement transformation, industry incubation, resource docking, talent cultivation, and professional services [6] - The cooperation agreement includes five core components: provision of physical space and supporting services by Dongcheng District, special support policies, establishment of an integrated platform for technology breakthroughs and achievement transformation, creation of a talent cultivation base, and a governance model ensuring efficient operation [6][7]

Group 1 - The "Xiehe Innovation Port" project aims to bridge the "last mile" of pharmaceutical innovation and has officially launched in Beijing's Dongcheng District, with a target scale of 4 billion yuan for the results transformation fund [1] - The project is a collaboration between the Chinese Academy of Medical Sciences Peking Union Medical College and Dongcheng District, marking a new phase of collaborative innovation in China's healthcare sector [1][2] - The project will focus on key areas such as innovative drugs, high-end medical devices, and artificial intelligence in healthcare, creating a closed-loop ecosystem from original innovation to industrial implementation [1] Group 2 - The first phase of the results transformation fund is set at 1 billion yuan, targeting investments in cutting-edge fields like gene and cell therapy and high-end medical devices [2] - The fund aims to leverage state-owned capital to attract social capital, providing comprehensive capital and professional service support for the transformation of scientific achievements [2] - The project is expected to cultivate a number of "Xiehe system" high-tech enterprises by 2030, forming a biopharmaceutical industry cluster [1][2]

Core Viewpoint - The report highlights that China's biopharmaceutical industry is transitioning from a "cost advantage" to "innovation-driven" growth, with overseas expansion becoming a second growth curve for innovative drug companies, indicating a shift from "heavy R&D" to "strong commercialization" [1][3]. Group 1: Industry Growth and Financial Performance - By the first three quarters of 2025, China's innovative drug sector revenue reached 48.83 billion yuan, reflecting a year-on-year growth of 22.1% [3]. - The total amount of foreign licensing for Chinese innovative drugs exceeded 100 billion USD in the first ten months of 2025, averaging nearly 300 million USD per day in international capital for Chinese original innovative drugs [3]. - Several companies have turned losses into profits, marking a period where the profitability of the Chinese biopharmaceutical industry is entering a realization phase [3]. Group 2: Evolution of Export Structure - The report outlines a significant transformation in China's biopharmaceutical exports, moving from low-value raw materials to high-value formulations, innovative drugs, and high-end medical devices [6][13]. - The overseas market strategy has diversified, focusing on consolidating developed markets while exploring emerging markets, with the U.S. remaining a primary target for innovative drugs [6][8]. Group 3: Outbound Strategies and Models - Chinese biopharmaceutical companies have developed a diverse set of outbound strategies, including independent expansion, co-development, licensing-out, NewCo models, and distribution agency, evolving from simple equity transactions to deeper participation in the global value chain [9][11]. - The limitations of traditional licensing-out models are becoming apparent, while Co-Co and NewCo models facilitate deeper involvement in global R&D, registration, and commercialization processes [9][11]. Group 4: Future Trends and Strategic Recommendations - The report identifies four key trends for 2026 and beyond: continuous evolution of technological frontiers, a shift from equity transactions to strategic symbiosis, the growing importance of emerging markets, and enhanced collaborative effects across the industry chain [14]. - Companies are encouraged to build long-term capabilities in compliance, commercialization, and brand image, moving from "industry outbound" to "global brand building" [17][18].